Suppr超能文献

抗增殖铂(IV)-四氮杂卟啉共轭物中铂(IV)的光致还原

Photoinduced reduction of Pt(IV) within an anti-proliferative Pt(IV)-texaphyrin conjugate.

作者信息

Thiabaud Grégory, Arambula Jonathan F, Siddik Zahid H, Sessler Jonathan L

机构信息

Department of Chemistry and Institute for Cellular and Molecular Biology, The University of Texas at Austin, 105 E. 24th Street- Stop A5300, Austin, Texas 78712-1224 (USA).

出版信息

Chemistry. 2014 Jul 14;20(29):8942-7. doi: 10.1002/chem.201403094. Epub 2014 Jun 24.

Abstract

In an effort to increase the stability and control the platinum reactivity of platinum-texaphyrin conjugates, two Pt(IV) conjugates were designed, synthesized, and studied for their ability to form DNA adducts. They were also tested for their anti-proliferative effects using wild-type and platinum-resistant human ovarian cancer cell lines (A2780 and 2780CP, respectively). In comparison to an analogous first-generation Pt(II) chimera, one of the new conjugates provided increased stability in aqueous environments. Using a combination of (1) H NMR spectroscopy and FAAS (flameless atomic-absorption spectrometry), it was found that the Pt(IV) center within this conjugate undergoes photoinduced reduction to Pt(II) upon exposure to glass-filtered daylight, resulting in an entity that binds DNA in a controlled manner. Under conditions in which the Pt(IV) complex is reduced to the corresponding Pt(II) species, these new conjugates demonstrated potent anti-proliferative activity in both test ovarian cancer cell lines.

摘要

为了提高铂-四氮杂卟啉共轭物的稳定性并控制铂的反应活性,设计、合成了两种Pt(IV)共轭物,并研究了它们形成DNA加合物的能力。还使用野生型和铂抗性人卵巢癌细胞系(分别为A2780和2780CP)测试了它们的抗增殖作用。与类似的第一代Pt(II)嵌合体相比,其中一种新的共轭物在水性环境中具有更高的稳定性。通过¹H NMR光谱和火焰原子吸收光谱法(FAAS)相结合的方法发现,该共轭物中的Pt(IV)中心在暴露于玻璃过滤的日光下会发生光诱导还原为Pt(II),从而产生一种以可控方式结合DNA的实体。在Pt(IV)络合物还原为相应的Pt(II)物种的条件下,这些新的共轭物在两种测试卵巢癌细胞系中均表现出强大的抗增殖活性。

相似文献

1
Photoinduced reduction of Pt(IV) within an anti-proliferative Pt(IV)-texaphyrin conjugate.
Chemistry. 2014 Jul 14;20(29):8942-7. doi: 10.1002/chem.201403094. Epub 2014 Jun 24.
2
Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate.
Bioorg Med Chem Lett. 2011 Mar 15;21(6):1701-5. doi: 10.1016/j.bmcl.2011.01.092. Epub 2011 Jan 26.
4
Visible light-activatable platinum(IV) prodrugs harnessing CD36 for ovarian cancer therapy.
Dalton Trans. 2023 Aug 8;52(31):10942-10950. doi: 10.1039/d3dt01292a.
6
Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery.
Biomaterials. 2011 Dec;32(34):9136-43. doi: 10.1016/j.biomaterials.2011.08.022. Epub 2011 Sep 1.
10
Mithplatins: Mithramycin SA-Pt(II) Complex Conjugates for the Treatment of Platinum-Resistant Ovarian Cancers.
ChemMedChem. 2023 Feb 1;18(3):e202200368. doi: 10.1002/cmdc.202200368. Epub 2022 Nov 22.

引用本文的文献

1
Recent Advances on Pt-Based Compounds for Theranostic Applications.
Molecules. 2024 Jul 23;29(15):3453. doi: 10.3390/molecules29153453.
2
Reduced texaphyrin: A ratiometric optical sensor for heavy metals in aqueous solution.
Front Chem Sci Eng. 2020 Feb;14(1):19-27. doi: 10.1007/s11705-019-1888-y. Epub 2020 Jan 8.
3
Promising heterometallic compounds as anticancer agents: Recent studies in vivo.
Curr Opin Chem Biol. 2023 Feb;72:102250. doi: 10.1016/j.cbpa.2022.102250. Epub 2022 Dec 23.
4
Lanthanide porphyrinoids as molecular theranostics.
Chem Soc Rev. 2022 Jul 18;51(14):6177-6209. doi: 10.1039/d2cs00275b.
6
Towards Imaging Pt Chemoresistance Using Gd(III)-Pt(II) Theranostic MR Contrast Agents.
ChemMedChem. 2021 Dec 14;16(24):3663-3671. doi: 10.1002/cmdc.202100389. Epub 2021 Aug 6.
7
Gd(iii)-Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy.
Chem Sci. 2020 Jan 28;11(9):2524-2530. doi: 10.1039/c9sc05937g.
8
An intramolecular photoswitch can significantly promote photoactivation of Pt(iv) prodrugs.
Chem Sci. 2021 Apr 1;12(19):6536-6542. doi: 10.1039/d0sc06839j.
9
Porphyrinoid Drug Conjugates.
Chem. 2020 Jul 9;6(7):1634-1651. doi: 10.1016/j.chempr.2020.06.019.
10
Photoactivatable Platinum-Based Anticancer Drugs: Mode of Photoactivation and Mechanism of Action.
Molecules. 2020 Nov 6;25(21):5167. doi: 10.3390/molecules25215167.

本文引用的文献

1
Nucleotide Platination Induced by Visible Light.
Angew Chem Int Ed Engl. 1999 May 17;38(10):1460-1463. doi: 10.1002/(SICI)1521-3773(19990517)38:10<1460::AID-ANIE1460>3.0.CO;2-Z.
2
A fluorescent probe for investigating the activation of anticancer platinum(IV) prodrugs based on the cisplatin scaffold.
Angew Chem Int Ed Engl. 2013 Nov 4;52(45):11785-9. doi: 10.1002/anie.201305734. Epub 2013 Sep 17.
4
Diazido mixed-amine platinum(IV) anticancer complexes activatable by visible-light form novel DNA adducts.
Chemistry. 2013 Jul 15;19(29):9578-91. doi: 10.1002/chem.201300374. Epub 2013 Jun 3.
5
Platinum(IV) prodrugs with haloacetato ligands in the axial positions can undergo hydrolysis under biologically relevant conditions.
Angew Chem Int Ed Engl. 2013 Jun 3;52(23):6059-62. doi: 10.1002/anie.201300640. Epub 2013 May 17.
6
NMR investigation of the spontaneous thermal- and/or photoinduced reduction of trans dihydroxido Pt(IV) derivatives.
Inorg Chem. 2013 Mar 4;52(5):2393-403. doi: 10.1021/ic302100x. Epub 2013 Feb 18.
7
A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
Chem Commun (Camb). 2012 Nov 11;48(87):10730-2. doi: 10.1039/c2cc34297a.
9
What do we know about the reduction of Pt(IV) pro-drugs?
J Inorg Biochem. 2012 Dec;117:220-9. doi: 10.1016/j.jinorgbio.2012.06.013. Epub 2012 Jul 2.
10
Pt(IV) complexes as prodrugs for cisplatin.
J Inorg Biochem. 2012 Feb;107(1):6-14. doi: 10.1016/j.jinorgbio.2011.10.012. Epub 2011 Nov 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验